FDA says "Continued use of Rezulin" posed an "unacceptable risk " to diabetes patients.

The following information is available on Rezulin.

Submit your claim for review.

Rezulin (Troglitazone) Withdrawn From Market

On March 21, 2000 the headof the FDA's center for Drug evaluation and Research stated that the "Continued use of Rezulin" posed an "unacceptable risk " to diabetes patients. At least 63 Rezulin users have died of liver failure. The total number of deaths is estimated to be as many as ten times higher than the reported 63 cases.

Rezulin was banned in England in December 1997, following the death of an American who took the drug. The drug manufacturer, Warner-Lambert, successfully fought a ban in the U.S. for 27 months before the FDA decided to prohibit sales of the drug on March 21, 2000.

If you need a liver transplant, have had a liver transplant or know someone who died as a result of using Rezulin (troglitazone) the popular diabetes drug you should speak to a lawyer to protect your rights and pursue compensation. We represent victims of Rezulin, a drug that won "fast track" FDA approval but unfortunatetly has been associated with liver failure and deaths. We will provide you with a free case assessment. All correspondence is confidential a

FDA Announcement

FDA today asked the manufacturer of Rezulin (troglitazone) -- a drug used to treat type 2 diabetes mellitus-- to remove the product from the market. The drug's manufacturer, Parke-Davis/Warner-Lambert, has agreed to FDA's request.